All Stories

  1. Safety assessment of immunization in pregnancy
  2. Neonatal encephalopathy: Case definition & guidelines for data collection, analysis, and presentation of maternal immunisation safety data
  3. Small for gestational age: Case definition & guidelines for data collection, analysis, and presentation of maternal immunisation safety data
  4. Low birth weight: Case definition & guidelines for data collection, analysis, and presentation of maternal immunization safety data
  5. Antenatal bleeding: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data
  6. Respiratory distress in the neonate: Case definition & guidelines for data collection, analysis, and presentation of maternal immunization safety data
  7. Gestational diabetes mellitus: Case definition & guidelines for data collection, analysis, and presentation of immunization safety data
  8. Failure to thrive: Case definition & guidelines for data collection, analysis, and presentation of maternal immunisation safety data
  9. Immunization in pregnancy clinical research in low- and middle-income countries – Study design, regulatory and safety considerations
  10. Spontaneous abortion and ectopic pregnancy: Case definition & guidelines for data collection, analysis, and presentation of maternal immunization safety data
  11. Fetal growth restriction: Case definition & guidelines for data collection, analysis, and presentation of immunization safety data
  12. Congenital microcephaly: Case definition & guidelines for data collection, analysis, and presentation of safety data after maternal immunisation
  13. Dysfunctional labor: Case definition & guidelines for data collection, analysis, and presentation of immunization safety data
  14. Spontaneous reports of vasculitis as an adverse event following immunization: A descriptive analysis across three international databases
  15. Adventitious agents and live viral vectored vaccines: Considerations for archiving samples of biological materials for retrospective analysis
  16. Live virus vaccines based on a vesicular stomatitis virus (VSV) backbone: Standardized template with key considerations for a risk/benefit assessment
  17. Postpartum haemorrhage: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data
  18. Congenital anomalies: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data
  19. Hypertensive disorders of pregnancy: Case definitions & guidelines for data collection, analysis, and presentation of immunization safety data
  20. Stillbirth: Case definition and guidelines for data collection, analysis, and presentation of maternal immunization safety data
  21. Neonatal death: Case definition & guidelines for data collection, analysis, and presentation of immunization safety data
  22. Non-reassuring fetal status: Case definition & guidelines for data collection, analysis, and presentation of immunization safety data
  23. Guideline for collection, analysis and presentation of safety data in clinical trials of vaccines in pregnant women
  24. Neonatal infections: Case definition and guidelines for data collection, analysis, and presentation of immunisation safety data
  25. Pathways to preterm birth: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data
  26. Guidance for the collection of case report form variables to assess safety in clinical trials of vaccines in pregnancy
  27. Global alignment of immunization safety assessment in pregnancy – The GAIA project
  28. Preterm birth: Case definition & guidelines for data collection, analysis, and presentation of immunisation safety data
  29. Maternal death: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data
  30. Effectiveness Study of Paromomycin IM Injection (PMIM) for the Treatment of Visceral Leishmaniasis (VL) in Bangladesh
  31. Global lessons from Nigeria’s ebolavirus control strategy
  32. Communicating Vaccine Safety During the Development and Introduction of Vaccines
  33. Mo1675 Pharmacokinetics and Tolerability of iOWH032, an Inhibitor of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Chloride Channel, in Normal Volunteers and Cholera Patients
  34. Standardization and simplification of vaccination records
  35. Introducing new vaccines in developing countries
  36. Template protocol for clinical trials investigating vaccines—Focus on safety elements
  37. Challenges and impact of conducting vaccine trials in Asia and Africa
  38. Scientific challenges and opportunities in developing novel vaccines for the emerging and developing markets: New Technologies in Emerging Markets, October 16th-18th 2012, World Vaccine Congress, Lyon
  39. Impact, Challenges, and Future Projections of Vaccine Trials in Africa
  40. Safety and Immunogenicity of DNA and MVA HIV-1 Subtype C Vaccine Prime-Boost Regimens: A Phase I Randomised Trial in HIV-Uninfected Indian Volunteers
  41. Prioritizing polio
  42. Safety reporting in developing country vaccine clinical trials—A systematic review
  43. Background morbidity in HIV vaccine trial participants from various geographic regions as assessed by unsolicited adverse events
  44. A Phase 1 Study to Evaluate the Safety and Immunogenicity of a Recombinant HIV Type 1 Subtype C-Modified Vaccinia Ankara Virus Vaccine Candidate in Indian Volunteers
  45. A Phase 1 Study to Evaluate the Safety and Immunogenicity of a Recombinant HIV Type 1 Subtype C Adeno-Associated Virus Vaccine